Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.00% to $475.08 Wednesday, on what proved to be an all-around rough trading ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...

Vertex (VRTX) delivered earnings and revenue surprises of 6.05% and 3.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report).

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average, which ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target boosted by analysts at Morgan Stanley from $473.00 to $476.00 in a note issued to investors on Tuesday, Benzinga reports.

From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know ...